About Alnylam Pharmaceuticals, Inc.
https://www.alnylam.comAlnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases.
CEO
Yvonne L. Greenstreet
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 565
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Stifel
Buy
Jefferies
Buy
Truist Securities
Buy
HC Wainwright & Co.
Buy
B of A Securities
Buy
Goldman Sachs
Buy
Grade Summary
Showing Top 6 of 24
Price Target
Institutional Ownership
FMR LLC
Shares:16.77M
Value:$6.15B
CAPITAL WORLD INVESTORS
Shares:16.43M
Value:$6.03B
VANGUARD GROUP INC
Shares:13.57M
Value:$4.98B
Summary
Showing Top 3 of 982
About Alnylam Pharmaceuticals, Inc.
https://www.alnylam.comAlnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $1.25B ▲ | $683.81M ▲ | $251.08M ▲ | 20.1% ▲ | $1.91 ▲ | $297.17M ▲ |
| Q2-2025 | $773.69M ▲ | $646.93M ▲ | $-66.28M ▼ | -8.57% ▲ | $-0.51 ▼ | $18.83M ▲ |
| Q1-2025 | $594.19M ▲ | $505.07M ▼ | $-57.48M ▲ | -9.67% ▲ | $-0.44 ▲ | $11.46M ▲ |
| Q4-2024 | $593.17M ▲ | $595.51M ▲ | $-83.76M ▲ | -14.12% ▲ | $-0.65 ▲ | $-140.91M ▼ |
| Q3-2024 | $500.92M | $491.92M | $-111.57M | -22.27% | $-0.87 | $-60.3M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $2.72B ▼ | $4.85B ▲ | $4.62B ▲ | $233.89M ▼ |
| Q2-2025 | $2.86B ▲ | $4.57B ▲ | $4.32B ▲ | $250.59M ▲ |
| Q1-2025 | $2.63B ▼ | $4.21B ▼ | $4.1B ▼ | $115.44M ▲ |
| Q4-2024 | $2.69B ▼ | $4.24B ▲ | $4.17B ▲ | $67.09M ▲ |
| Q3-2024 | $2.78B | $4.21B | $4.17B | $32.35M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $251.08M ▲ | $325.11M ▲ | $501.11M ▲ | $-448.35M ▼ | $376.94M ▲ | $312.97M ▲ |
| Q2-2025 | $-66.28M ▼ | $153.73M ▲ | $-141.38M ▼ | $53.76M ▲ | $93.61M ▲ | $139.44M ▲ |
| Q1-2025 | $-57.48M ▲ | $-118.31M ▼ | $113.77M ▲ | $44.08M ▲ | $53.6M ▲ | $-127.28M ▼ |
| Q4-2024 | $-83.76M ▲ | $-94.66M ▼ | $-52.91M ▼ | $31M ▼ | $-133.85M ▼ | $-103.76M ▼ |
| Q3-2024 | $-111.57M | $43.71M | $-30.25M | $102.75M | $131.31M | $39.52M |
Revenue by Products
| Product | Q3-2024 | Q4-2024 | Q1-2025 | Q2-2025 |
|---|---|---|---|---|
 GIVLAARI | $70.00M ▲ | $60.00M ▼ | $70.00M ▲ | $80.00M ▲ |
 ONPATTRO | $50.00M ▲ | $0 ▼ | $50.00M ▲ | $50.00M ▲ |
 Product | $420.00M ▲ | $450.00M ▲ | $470.00M ▲ | $670.00M ▲ |
Revenue by Geography
| Region | Q3-2024 | Q4-2024 | Q1-2025 | Q2-2025 |
|---|---|---|---|---|
 Europe | $70.00M ▲ | $70.00M ▲ | $80.00M ▲ | $90.00M ▲ |
 NonUS Or Europe | $20.00M ▲ | $30.00M ▲ | $30.00M ▲ | $40.00M ▲ |
 UNITED STATES | $170.00M ▲ | $180.00M ▲ | $200.00M ▲ | $360.00M ▲ |
CEO
Yvonne L. Greenstreet
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 565
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Stifel
Buy
Jefferies
Buy
Truist Securities
Buy
HC Wainwright & Co.
Buy
B of A Securities
Buy
Goldman Sachs
Buy
Grade Summary
Showing Top 6 of 24
Price Target
Institutional Ownership
FMR LLC
Shares:16.77M
Value:$6.15B
CAPITAL WORLD INVESTORS
Shares:16.43M
Value:$6.03B
VANGUARD GROUP INC
Shares:13.57M
Value:$4.98B
Summary
Showing Top 3 of 982